Akiko Ogiya1, Kieko Yamazaki1, Rie Horii2, Tadahiko Shien3, Yoshiya Horimoto4, Norikazu Masuda5, Touko Inao6, Mitsuchika Hosoda7, Naoko Ishida7, Tomofumi Osako8,9, Masato Takahashi10, Yumi Endo11, Yuichiro Miyoshi3, Hiroyuki Yasojima5, Nobumoto Tomioka10, Hiroko Yamashita12. 1. Breast Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 2. Division of Pathology, Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan. 3. Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan. 4. Department of Breast Oncology, Juntendo University School of Medicine, Tokyo, Japan. 5. Department of Surgery, Breast Oncology, NHO Osaka National Hospital, Osaka, Japan. 6. Department of Breast and Endocrine Surgery, Graduate School of Medical Science Kumamoto University, Kumamoto, Japan. 7. Breast Surgery, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo, 060-8648, Japan. 8. Department of Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan. 9. Kumamoto Shinto General Hospital, Kumamoto, Japan. 10. Department of Breast Surgery, NHO Hokkaido Cancer Center, Sapporo, Japan. 11. Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. 12. Breast Surgery, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo, 060-8648, Japan. hirokoy@huhp.hokudai.ac.jp.
Abstract
BACKGROUND: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. METHODS: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. RESULTS: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months. CONCLUSION: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.
BACKGROUND: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. METHODS: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. RESULTS: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months. CONCLUSION: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.
Entities:
Keywords:
Breast cancer; Endocrine therapy; Estrogen receptor-positive; Post-relapse survival; Prognosis
Authors: Zuhair D Hammood; Abdulwahid M Salih; Snur Othman; Berwn A Abdulla; Shvan H Mohammed; Fahmi H Kakamad; Sharo Naqar Journal: Int J Surg Case Rep Date: 2022-02-12